A battle over how to treat childhood obesity is brewing between those in favour and others who warn of the effects on growing bodies ...

Debate over childhood obesity treatments: weight-loss drugs vs. lifestyle changes, with concerns about long-term effects.

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Novo Nordisk A/S dominates in diabetes and weight-loss drugs, particularly with semaglutide, making it a strong buy. Record investments in 2024 to enhance supply chain and production capacity ...

I’d recommend checking out my last article, where I took a deeper look at some of Novo Nordisk’s most promising pipeline treatments for diabetes, like IcoSema or oral semaglutide. Obesity ...

While Wegovy (semaglutide) sales more than doubled to DKK 19.87 billion ($2.78 billion) in the three-month period, that was slightly below estimates and Novo Nordisk said is now anticipating ...

CagriSema combines the GLP-1 agonist semaglutide in Novo Nordisk's blockbuster weight-loss drug Wegovy with dual amylin and calcitonin receptor agonist cagrilintide. The company is hoping that the ...

Novo Nordisk is planning a new Phase III trial for CagriSema, the company’s next-generation obesity drug touted as a potential successor to Wegovy (semaglutide), as the company aims to quell ...

CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

Good day, and thank you for standing by. Welcome to the full-year 2024 Novo Nordisk earnings conference call. [Operator instructions] Please be advised that today's conference is being recorded.